Of note, these 3-Mb deletions include the LZTR1 gene but not SMARCB1. Remarkably, patients with these 3-Mb deletions have a lower risk for developing schwannomas as compared to the general population [398]. This evidence concerns the gene SMARCB1 and schwannoma.